Nonfatal myocardial infarction is, by itself, an inappropriate end point in clinical trials in cardiology.

@article{Fleiss1990NonfatalMI,
  title={Nonfatal myocardial infarction is, by itself, an inappropriate end point in clinical trials in cardiology.},
  author={Joseph L. Fleiss and J. Thomas Bigger and Michael McDermott and J. Philip Miller and Timothy H Moon and Arthur J. Moss and David Oakes and Linda M. Rolnitzky and Terry M. Therneau},
  journal={Circulation},
  year={1990},
  volume={81 2},
  pages={
          684-5
        }
}
In a number of double-blinded, clinical trials in cardiology,1-4 the occurrence of a nonfatal myocardial infarction has served as a secondary end point and, in at least one,5 as the primary end point. We believe that this practice may be inappropriate. An assumption underlying the separate analysis of nonfatal infarction is that there may be pathophysiological differences between fatal and nonfatal infarctions so that the effect of treatment on one of these outcomes may be different from the… CONTINUE READING